November 18, 2020

The Honorable Andrei Iancu
Under Secretary of Commerce for Intellectual Property and
Director of the U.S. Patent and Trademark Office
United States Patent and Trademark Office
600 Dulany Street
Alexandria, Virginia 22314

RE: Comments of Kaia Health on the U.S. Patent and Trademark Office’s Request for Comments on Discretion to Institute Trials Before the Trial and Appeal Board [Docket No. PTO-C-2020-0055]

Dear Vice Chief Weidenfeller:

Kaia Health writes in response to the Department of Commerce U.S. Patent and Trademark Office’s (USPTO) request for comment regarding the discretion to institute trials before the Patent Trial and Appeal Board.¹

Through the precedential decisions and policies discussed in the Request for Comments, the U.S. Patent and Trademark Office (“PTO”) has frustrated the goals and utility of inter partes review (“IPR”). The PTO is unraveling Congress’s efforts to reduce the harms caused by low-quality patents and abusive litigation. As the Patent Trial and Appeal Board (“PTAB”) increasingly exercises its discretion to deny IPR petitions, it is leaving many invalid patents unchallenged. And the nation’s innovators are suffering the consequences of these PTO efforts to shield invalid patents from review. Rates of abusive litigation are steadily rising, and IPR is often no longer a viable, affordable alternative to challenge low-quality patents. Instead of continuing down this path by codifying current policies and practices, the PTO should re-prioritize patent quality and restore the IPR system to its proper focus—resolving the problems of erroneously-granted patents.

The IPR System is Critically Important to Startups and Small Business Innovators and Had Been Working Well

When Congress passed the America Invents Act (“AIA”), a core motivating goal was “to establish a more efficient and streamlined patent system that will improve patent quality and limit unnecessary and counterproductive litigation costs.”² And Congress succeeded, creating an IPR system that worked—to reduce the high costs of challenging low-quality patents, open up invalidity defenses to those who could not previously afford them, discourage the assertion of low-quality patents, and level the playing field in patent assertion.

The existence of a healthy IPR system generated numerous benefits. It was becoming more difficult to leverage the high costs of district court litigation to coerce startups and small business innovators into settling frivolous cases. As such, it became less profitable to engage in abusive practices. Indeed, we had

¹ United States Patent and Trademark Office, Request for Comments on Discretion to Institute Trials Before the Trial and Appeal Board, 85 FR 66502 (October 20, 2020).
been seeing fewer abusive patent demands since IPR was established. The AIA led to an estimated $2.6 billion in direct savings in patent litigation costs over five years. And that savings further translated into a nearly $3 billion increase in U.S. business activity.

For us, the mere option of an IPR was also an effective tool to persuade abusive patent assertion entities ("PAEs") to walk away or settle on more reasonable terms. While our preference would always be to avoid paying to “use” invalid patents, anything that reduces the costs we face from abusive patent assertion still has value. Even before filing an IPR petition, we have been able to explain to those wielding invalid patents why and how their assertions lack merit. With confidence that we could prepare and file a winning IPR, that fact alone helped us avoid costs and risks of abusive litigation.

Recent PTO Policies Have Weakened IPR, Fostering Abuse of the Patent System

Since the PTAB started down the path of exercising its discretion to deny meritorious petitions, the benefits we had seen due to IPR are eroding. By imposing a constellation of imbalanced requirements on IPR petitioners, and going beyond the carefully negotiated requirements in the statute, the PTAB has increased costs on innovators, created uncertainty, and left invalid patents in force to be asserted in district court.

The PTO’s current policies and practices for discretionary denials directly conflict with the AIA’s purpose. On their face, these policies are concerning. When the PTAB becomes aware of an invalid patent that fails to satisfy the statutory criteria, it should act to cancel it. Indeed, the core purpose of the IPR is “to weed out bad patent claims efficiently.” That purpose is subverted by current PTO policies which impose requirements on IPR petitions that are inconsistent with the statute.

The PTAB’s approach to shielding invalid patents from scrutiny has not gone unnoticed by PAEs. Abusive patent litigation is back on the rise and the problem of forum shopping is rapidly growing. Defending even frivolous litigation is very expensive—it can cost anywhere from $1.8 to $4.5 million to take a PAE case to trial, orders of magnitude more than what most startups and small companies can afford, and far greater than an IPR. But PAE litigation has grown nearly 40 percent this year compared to last, and nearly 50 percent compared to 2018. And since the NHK Spring Co. v. Intrix-Plex Techs., Inc. decision was designated as precedential, there has been more than a 200 percent increase in new PAE cases filed in the Western District of Texas—a jurisdiction where patent owners can effectively IPR-proof their assertions lack merit. With confidence that we could prepare and file a winning IPR, that fact alone helped us avoid costs and risks of abusive litigation.

---

3 See also, e.g., Patent Review is Working for Startups, Engine, https://innovatewithoutfear.engine.is/wp-content/uploads/2020/01/IPR-is-working-one-pager.pdf (showing less NPE litigation since IPR went into effect).
5 Thrv, Inc v. Click-To-Call Techs., ___ U.S. ___, 140 S. Ct. 1367, 1374 (2020).
9 IPR2018-00752 (Sept. 12, 2018) (designated precedential May 7, 2019).
their patents by playing local rules off of PTO policies.\textsuperscript{10} This resurgence in the sort of problematic behavior that motivated IPR in the first place should send a strong signal that the PTO’s current policies are askew.

**Instead of Codifying Rules that Shield Invalid Patents, PTO Should Re-Prioritize Patent Quality**

Instead of continuing on its current trajectory, the PTO should return its focus to promoting patent quality, and the PTAB should institute each and every IPR petition that satisfies the statutory threshold by establishing “a reasonable likelihood” that at least one claim in the challenged patent is invalid.\textsuperscript{11} We urge the PTO to not codify the policies and practices mentioned in the Request for Comments. Instead, we encourage the Office to unwind its recent efforts which have weakened IPR and made it harder to challenge invalid patents.

With the PTO correctly focused on patent quality, and IPR available to “weed out” invalid patents that should never have been issued, we can get back to our work of innovation, economic growth, research and development, manufacturing, hiring, and hopefully contributing to the country’s recovery from theeconomic downturn caused by the current pandemic. But to do that, we need to not be bogged down by invalid patents and abusive patent assertions. That is where the PTO can, and hopefully will, come in.

Respectfully submitted,

Kaia Health
134 N 4th Street
2nd Floor
Brooklyn, NY 11249


\textsuperscript{11} 35 U.S.C. § 314(a).